Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy PRA Health Sciences stock | 110

Own PRA Health Sciences stock in just a few minutes.

Posted

Fact checked

PRA Health Sciences, Inc is a diagnostics & research business based in the US. PRA Health Sciences shares (PRAH) are listed on the NASDAQ and all prices are listed in US Dollars. PRA Health Sciences employs 17,500 staff and has a trailing 12-month revenue of around USD$3.1 billion.

How to buy shares in PRA Health Sciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for PRA Health Sciences. Find the stock by name or ticker symbol: PRAH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until PRA Health Sciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$110, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of PRA Health Sciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of PRA Health Sciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted PRA Health Sciences's share price?

Since the stock market crash in March caused by coronavirus, PRA Health Sciences's share price has had significant positive movement.

Its last market close was USD$110, which is 2.65% up on its pre-crash value of USD$107.09 and 87.49% up on the lowest point reached during the March crash when the shares fell as low as USD$58.67.

If you had bought USD$1,000 worth of PRA Health Sciences shares at the start of February 2020, those shares would have been worth USD$624.08 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,070.30.

PRA Health Sciences share price

Use our graph to track the performance of PRAH stocks over time.

PRA Health Sciences shares at a glance

Information last updated 2020-10-16.
Latest market closeUSD$110
52-week rangeUSD$58.67 - USD$113.41
50-day moving average USD$104.2661
200-day moving average USD$98.276
Wall St. target priceUSD$113.46
PE ratio 34.0462
Dividend yield N/A (0%)
Earnings per share (TTM) USD$3.273

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Tastyworks
$0
Stocks, Options, ETFs, Futures
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy PRA Health Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

PRA Health Sciences price performance over time

Historical closes compared with the close of $110 from 2020-10-16

1 week (2020-10-22) -0.25%
1 month (2020-09-29) 11.93%
3 months (2020-07-29) 2.61%
6 months (2020-04-29) 11.45%
1 year (2019-10-29) 10.62%
2 years (2018-10-29) 15.91%
3 years (2017-10-27) 34.08%
5 years (2015-10-29) 212.68%

Is PRA Health Sciences under- or over-valued?

Valuing PRA Health Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PRA Health Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

PRA Health Sciences's P/E ratio

PRA Health Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, PRA Health Sciences shares trade at around 34x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

PRA Health Sciences's PEG ratio

PRA Health Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2248. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PRA Health Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

PRA Health Sciences's EBITDA

PRA Health Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$430.5 million.

The EBITDA is a measure of a PRA Health Sciences's overall financial performance and is widely used to measure a its profitability.

PRA Health Sciences financials

Revenue TTM USD$3.1 billion
Operating margin TTM 9.92%
Gross profit TTM USD$1.5 billion
Return on assets TTM 5.36%
Return on equity TTM 18.22%
Profit margin 6.86%
Book value $18.255
Market capitalisation USD$7.1 billion

TTM: trailing 12 months

Shorting PRA Health Sciences shares

There are currently 935,867 PRA Health Sciences shares held short by investors – that's known as PRA Health Sciences's "short interest". This figure is 3.8% down from 972,460 last month.

There are a few different ways that this level of interest in shorting PRA Health Sciences shares can be evaluated.

PRA Health Sciences's "short interest ratio" (SIR)

PRA Health Sciences's "short interest ratio" (SIR) is the quantity of PRA Health Sciences shares currently shorted divided by the average quantity of PRA Health Sciences shares traded daily (recently around 309889.73509934). PRA Health Sciences's SIR currently stands at 3.02. In other words for every 100,000 PRA Health Sciences shares traded daily on the market, roughly 3020 shares are currently held short.

However PRA Health Sciences's short interest can also be evaluated against the total number of PRA Health Sciences shares, or, against the total number of tradable PRA Health Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PRA Health Sciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 PRA Health Sciences shares in existence, roughly 10 shares are currently held short) or 0.0215% of the tradable shares (for every 100,000 tradable PRA Health Sciences shares, roughly 22 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against PRA Health Sciences.

Find out more about how you can short PRA Health Sciences stock.

PRA Health Sciences share dividends

We're not expecting PRA Health Sciences to pay a dividend over the next 12 months.

PRA Health Sciences share price volatility

Over the last 12 months, PRA Health Sciences's shares have ranged in value from as little as $58.67 up to $113.41. A popular way to gauge a stock's volatility is its "beta".

PRAH.US volatility(beta: 1.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PRA Health Sciences's is 1.0458. This would suggest that PRA Health Sciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

PRA Health Sciences overview

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company has a partnership with The Leukemia & Lymphoma Society to launch a clinical trial for developing treatments for children with relapsed acute leukemia. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site